Strategic fit Target hospitals and cath labs focused on contrast dye reduction to protect kidney health, leveraging Osprey’s DyeVert technology as a differentiator in IC AKI prevention.

Funding leverage Capitalize on Osprey's history of funding and growth signals to position the company for partnerships with larger medical device firms or health systems seeking innovative revenue-positive AKI reduction solutions.

Public/Private expansion Explore opportunities across public and private healthcare networks, including large-scale suppliers and distributors connected to Premier Inc. and GE Healthcare alliances, to widen market access.

Clinical impact metrics Highlight measurable outcomes such as reduced contrast usage and AKI risk with DyeVert, offering compelling value propositions for procurement and outcomes-based contracting.

Growth signals Monitor company milestones, partnerships, and awards as buying signals for distributors and system integrators seeking validated, early-stage medical device innovations.